GW Pharmaceuticals

What GW Pharmaceuticals does

GW Pharmaceuticals plc was a United Kingdom-based biopharmaceutical company founded in 1998 and headquartered in Cambridge, UK. The company specialized in the discovery, development, and commercialization of novel cannabinoid-based prescription therapeutics, with its flagship product Epidiolex — the first FDA-approved plant-derived cannabidiol (CBD) prescription medication, indicated for severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome following its 2018 regulatory approval. Underlying Epidiolex was proprietary expertise in pharmaceutical-grade CBD formulation, including standardized dosing, purity controls, and clinical validation that differentiate a regulated prescription drug from consumer CBD products.

The company monetized Epidiolex through traditional pharmaceutical distribution channels — specialty pharmacies, hospitals, and licensed healthcare providers — selling to patients with treatment-resistant severe epilepsy. Revenue mechanics were product-sale driven under an FDA-approved prescription label, with marketing executed through healthcare-provider engagement, medical conferences, and scientific publications. GW also extended its research into adjacent indications, notably Opioid Use Disorder in collaboration with Astellas Pharma and Opiant Pharmaceuticals, and supported next-generation CBD drug product development with partners such as dsm-firmenich (CBtru intermediate).

GW Pharmaceuticals was publicly traded on NASDAQ (ticker: GWPH) until its $7.2 billion acquisition by Jazz Pharmaceuticals in 2021, after which it has operated as a wholly-owned subsidiary of Jazz within its neuroscience and epilepsy franchise. At the time of acquisition the company had 1,001–5,000 employees and was led by founder Geoffrey Guy along with a bench including James Noble (Deputy Chairman), Douglas Snyder (CLO), Scott Giacobello (CFO), Volker Knappertz (CMO), Julian Gangolli (President of North America), and Adam George (UK Managing Director).

Name

GW Pharmaceuticals

Legal name

GW Pharmaceuticals plc

Website

https://gwpharm.com

Company type

Private

Founded year

1998

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

GW Pharmaceuticals was a UK-based biopharmaceutical company that developed Epidiolex, the first FDA-approved plant-derived CBD prescription drug for severe epilepsy forms including Dravet and Lennox-Gastaut syndromes, before being acquired by Jazz Pharmaceuticals for $7.2 billion in 2021.

Ownership category

akta.pro rank

Product category

Cannabinoid Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Cannabinoid pharmaceuticals
• Epilepsy therapeutics
• CBD medications
• Biopharmaceutical development
• Prescription cannabis

Headquarters

HQ city

Histon

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of FDA-approved prescription medications, specifically Epidiolex for severe epilepsy treatment

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

GW Pharmaceuticals develops and commercializes FDA-approved prescription medications derived from cannabinoids, with its primary product being Epidiolex, a pharmaceutical-grade CBD oral solution approved for the treatment of severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome. The company also maintained a research pipeline exploring novel cannabinoid therapeutics for additional indications such as opioid use disorder.

Product overview

GW Pharmaceuticals was a pharmaceutical company specializing in the development and commercialization of cannabinoid-based prescription medicines. The company's primary product was Epidiolex, an FDA-approved CBD-based medication for severe epilepsy. GW Pharmaceuticals was acquired by Jazz Pharmaceuticals for $7.2 billion in 2021.

Differentiator

Problem solved

Functional benefit

Brands

• Epidiolex: FDA-approved CBD-based prescription medication for severe forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.

Products and services

• Epidiolex FDA-approved CBD-based prescription medication indicated for the treatment of severe forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. It is a pharmaceutical-grade oral solution of cannabidiol designed for patients with treatment-resistant severe epilepsies.

Quantifiable outcome

• FDA approval for treatment of Dravet syndrome and Lennox-Gastaut syndrome

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Jazz PharmaceuticalsflagshipStrategic or Co-development Partner · 1 January 2021Jazz Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion in 2021, gaining Epidiolex, the FDA-approved CBD-based prescription medication for severe epilepsy forms. This acquisition significantly expanded Jazz's neuroscience portfolio and cannabis-based pharmaceutical capabilities.
• Astellas PharmacoreStrategic or Co-development PartnerGW Pharmaceuticals is actively working on clinical trials for Opioid Use Disorder treatments alongside Astellas Pharma and Opiant Pharmaceuticals, as part of a robust pipeline of over 10 key pharmaceutical companies in this domain.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Marinus Pharmaceuticals: Marinus developed Ztalmy (ganaxolone), an FDA-approved treatment for CDKL5 deficiency disorder, a rare developmental epilepsy. It is comparable as a small CNS specialty pharma focused specifically on rare/seizure disorders.
• UCB: UCB is a global biopharmaceutical company whose core neuroscience franchise includes epilepsy treatments (e.g., Briviact, Vimpat, Keppra). It is the closest direct peer given shared focus on branded prescription neurology/epilepsy drugs distributed via the same specialty pharmacy channels.
• Biohaven Pharmaceuticals: Biohaven is a CNS-focused biopharmaceutical company, originally spun out and later acquired by Pfizer, with branded neurology therapies distributed through specialty pharmacy — overlapping with GW's specialty CNS distribution model.
• SK Life Science: SK Life Science markets cenobamate (Xcopri) for focal-onset seizures in the US and operates in the branded prescription epilepsy space with comparable patient overlap to Epidiolex.
• Zogenix: Zogenix developed Fintepla (fenfluramine) for Dravet and Lennox-Gastaut syndromes — the same indications targeted by Epidiolex — making it the most direct patient-overlap competitor in severe pediatric epilepsy before its acquisition by UCB.

Broad incumbents

• Jazz Pharmaceuticals: Jazz is the parent of GW Pharmaceuticals after the $7.2B 2021 acquisition and the commercial distributor of Epidiolex. It is broadly comparable as the acquirer/owner of GW's CBD epilepsy franchise and operates an overlapping CNS/neuroscience portfolio including sleep and rare disease medicines.
• AbbVie / Allergan: AbbVie (post-Allergan acquisition) markets a deep CNS portfolio including therapies for neurological conditions and operates a global specialty neurology salesforce that overlaps with GW's distribution into neurology/epilepsy prescribers.
• Eisai Co., Ltd. Eisai is a major Japanese pharmaceutical company with a substantial neurology franchise including Fycompa (perampanel) for epilepsy. It is comparable as a broad incumbent operating in branded neurology/CNS prescription drugs overlapping with GW's epilepsy focus.

Emerging players

• Canopy Growth Corporation: Canopy Growth is a major cannabis company with pharmaceutical and medical-cannabis divisions aiming at prescription-grade cannabinoid therapies. It is comparable as an emerging player pursuing FDA-grade cannabinoid drug development adjacent to GW's established CBD pharmaceutical franchise.
• Tilray Brands: Tilray operates a pharmaceutical cannabis platform including GMP-cannabinoid production for clinical trials and prescription channels. It is comparable as an emerging cannabis pharma player pursuing regulated cannabinoid medicines in a manner adjacent to GW.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gw-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GW Pharmaceuticals